StreetAlpha.app
Home › Stocks › ARDX

Ardelyx, Inc. (ARDX)

Healthcare
$3.18
▲ +3.58%
LAST CLOSE · NOV 17

Ardelyx sells IBSRELA and XPHOZAH, prescription medicines for irritable bowel syndrome and elevated phosphorus in dialysis patients. It last closed at $3.18 on Nov 17, up 3.58% on the day. In the past 30 days there were 2 dark pool prints totaling $567K, the largest $348K.

AI Auto Pilots
Is ARDX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$468.2M
+17.6% vs a year ago
Net income
−$55.5M
−11.8% margin
EPS (diluted)
−$0.23
Free cash flow
−$16.0M
−3.4% margin
Valuation
Market cap
$799.4M
251.4M shares
P/E
–
No P/E while losing money
Price to sales
1.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$46.3M
At Sep 30
Debt
$252.4M
At Sep 30
Shareholder equity
$164.0M
Shares outstanding
251.4M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $10.1M$10.1MFY2021FY2022: $52.2M$52.2MFY2022FY2023: $124.5M$124.5MFY2023FY2024: $333.6M$333.6MFY2024FY2025: $407.3M$407.3MFY2025

From ARDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ARDX in the past 90 days, not enough for a consensus
Average 12-month target
$11.00
▲ 245.9% upside

Based on 1 analyst who set a price target on ARDX in the past 90 days. The average target is $11.00, with a high of $11.00 and a low of $11.00, compared with the last close of $3.18.

$2$5$9$12PAST 22 TRADING DAYS12-MONTH TARGETSHIGH $11AVG $11LOW $11Aug 6LAST CLOSE+12 MO$2$5$9$12PAST 22 DAYSTARGETSHIGH $11AVG $11LOW $11Aug 6LAST CLOSE+12 MO
Highest target$11.00
Average target$11.00
Lowest target$11.00
Latest rating changes
BTIGTarget lowered
Nov 10Buy$14 → $11
WedbushReiterated
Aug 19Buy$9
WedbushReiterated
Aug 18Buy$9
Piper SandlerMaintained
Aug 17Buy$15
CitigroupMaintained
Aug 10Buy$11
DateFirmActionRatingPrice target
Nov 10BTIGTarget loweredBuy$14 → $11
Aug 19WedbushReiteratedBuy$9
Aug 18WedbushReiteratedBuy$9
Aug 17Piper SandlerMaintainedBuy$15
Aug 10CitigroupMaintainedBuy$11
Loading…

Technical Analysis

ARDX · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 59% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the Pivot at $3.14, and the nearest resistance the Pivot R1 at $3.23.

Short trendNeutral
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 4.7%/day
Key levels
$8.4052 week high+164.2%
$5.06200 day average+59.1%
$3.92100 day average+23.3%
$3.35Swing high (Oct 15)+5.3%
$3.2550 day average+2.2%
$3.23Pivot R1+1.6%
$3.18Last close
$3.14Pivot−1.3%
$3.09Pivot S1−2.8%
$3.0720 day average−3.5%
$3.05Swing low (Oct 19)−4.1%
$2.8052 week low−11.9%
Indicators
RSI (14)51.97Middle of its rangeNeutral
MACD-0.05Above its signal lineBullish
Stochastic52.2Middle of its rangeNeutral
ADX (14)18.0No clear trend
Williams %R-36.7Oversold below −80, overbought above −20Neutral
CCI (20)77.5Oversold below −100, overbought above 100Neutral
Rate of change+5.0%Change over 10 sessionsBullish
ATR (14)$0.15Typical daily range, 4.7% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARDX

What happened before

See how ARDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ARDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ARDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ARDX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$567K
Largest print
$348K
Loading…

ARDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼100 buying vs 141 selling
  • ▲Held by funds +2.4 pts
  • ▼Funds holding -25
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding225250−10.0%
In funds' top 1000–
Held by funds73.0%70.6%+2.4 pts
New / increased31 / 6941 / 87−21.9%
Reduced / sold out86 / 5587 / 34+16.5%
Put/call ratio18.490.39+4695.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARDX is in one of them and how their past ARDX trades turned out.

ARDX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARDX in an article yet. Here's the latest on the wider market.

ARDX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Mar 22
Who traded ARDX · since 2025
Latest 1 filing
$1K – $15KTraded Feb 24, 2025Filed Mar 22, 2025
PersonTypeAmountTradedFiledDelay
Ashley MoodyR · FLSell$1K – $15KFeb 24, 2025Mar 22, 202526 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Ardelyx

Ardelyx is a biopharmaceutical company based in Fremont, California. It sells two prescription medicines, both made from the active ingredient tenapanor. IBSRELA treats adults with irritable bowel syndrome with constipation, and XPHOZAH lowers phosphorus levels in adults with chronic kidney disease who are on dialysis. The company sells these medicines in the United States and is also studying tenapanor for chronic idiopathic constipation.

Headquarters
Fremont, CA
Founded
2007